Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone intravitreal implant plus aflibercept versus aflibercept alone for diabetic macular edema
ChiCTR2500102114Phase 2Completed
- Sponsor
- Tangdu Hospital
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aflibercept and dexamethasone in diabetic macular edema (DME) (2 arms), sponsored by Tangdu Hospital. Primary endpoint: Best corrected visual acuity (BCVA) at Week 24. Started May 2025; status: completed.
02
Drugs
afliberceptdexamethasone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2500102114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102114.